Table 3.
Predictive effect of TP53 mutation status on overall survival (OS) according to histology.
| Non‐Adenocarcinoma (n = 349) | Adenocarcinoma (n = 175) | Treatment effect by mutation status | ||||
|---|---|---|---|---|---|---|
| Treatment am | Observation arm | Treatment arm | Observation arm | HR, [95% CI] (a) | p‐value | |
| Wild‐Type TP53 | ||||||
| nb deaths/total | 53/90 | 53/96 | 36/54 | 35/63 | 1.00, [0.74–1.35] | p = 1.00 |
| HR, [95% CI] (a) | 0.99, [0.67–1.45] (b) | 1.00, [0.62–1.62] (b) | ||||
| p‐value | p = 0.95 | p = 1.00 | ||||
| Mutant TP53 | ||||||
| nb deaths/total | 66/91 | 44/72 | 21/29 | 16/29 | 1.36, [0.97–1.91] | p = 0.07 |
| HR, [95% CI] (a) | 1.33, [0.90–1.96] (b) | 1.46, [0.74–2.88] (b) | ||||
| p‐value | p = 0.15 | p = 0.28 | ||||
| Treatment effect by histology | ||||||
| HR, [95% CI] (a) | 1.15 [0.87–1.51] | 1.13 [0.76–1.68] | ||||
| p‐value | p = 0.32 | p = 0.55 | ||||
(a): HR for death, treatment vs Observation, [95% CI].
(b): test for equality of interaction of treatment by TP53 status in the 2 histology subgroups : p = 0.88.